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Abstract Jurkat T cells die of apoptosis upon exposure to anti-Fas mAb. Here we show that although the alternative complement pathway generally 
does not attack homologous cells, anti-Fas-induced apoptotic Jurkat T cells were attacked antibody-independently by the alternative pathway of 
human complement and opsonized with iC3b, which is a ligand of the complement receptor type 3 (CR3) of phagocytes. These results uggest that 
apoptotic ells become the targets of the homologous alternative complement pathway, which facilitates the clearance ofapoptotic cells by phagocytes. 
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1. Introduction 2. Materials and methods 
Apoptosis, aform of programmed cell death, plays an impor- 
tant role in immune responses, uch as the negative selection 
of T lymphocytes in thymus and target cell killing by cytotoxic 
T lymphocytes [1,2]. The Fas antigen (Fas), is expressed in 
immature T cells and transduces signals leading to apoptosis 
[3]. The cross-linking ofFas by anti-Fas mAb has been used for 
investigating the molecular mechanism leading to the apoptosis 
of T cells [4]. The physiological significance of apoptosis i the 
rapid processing of apoptotic ells by phagocytes to protect 
normal tissues from damage by the harmful contents of dying 
cells [5]. Although the molecular mechanism leading to apopto- 
sis has been throughly investigated, little is known about the 
mechanism by which a phagocyte discriminates between apop- 
totic and normal self cells. 
Complement is a humoral immune system and composed of 
two independent enzyme cascades, termed the classical and the 
alternative pathways. The classical complement pathway is 
mainly activated by immune complexes, whereas the alternative 
pathway is activated antibody-independently by activator mol- 
ecules on heterologous cells, such as lipopolysaccharides and 
proteoglycans [6]. The activation of the alternative complement 
pathway does not proceed on homologous cells, because they 
lack activator molecules and they express the complement reg- 
ulatory membrane proteins, decay-accelerating factor (DAF) 
and membrane cofactor protein (MCP) on their membrane 
[7,8]. We reported that apoptotic human umbilical vein endo- 
thelial cells (HUVEC) can activate the alternative pathway of 
human complement [9]. These findings prompted us to investi- 
gate whether apoptosis also allows T cells to activate homolo- 
gous complement. Here, we report hat anti-Fas-induced apop- 
totic Jurkat cells, a malignant human T cell line, activate the 
homologous alternative complement pathway and are depos- 
ited with iC3b, the ligand of the complement receptor type 3 
(CR3) of phagocytes. 
*Corresponding author. Fax: (81) (11) 706 4990. 
2.1. Materials 
The anti-Fas mAb (CH-1 i and 2D1) were obtained from Medical & 
Biological Lab., Nagoya nd Dr. S. Takahashi, Sapporo Medical Uni- 
versity, respectively. Horseradish peroxidase-conjugated goat anti-rab- 
bit IgG and FITC-labelled goat anti-mouse IgG F(ab')2 were obtained 
from TAGO. Goat anti-C3 antibody was obtained from Cappel. Anti- 
C3b mAb (C5-G) was donated by Prof. T. Fujita, Fukushima Medical 
School. Rabbit polyclonal nti-C3d antibody was prepared in our lab- 
oratory. 
2.2. Cell culture 
Jurkat cells, E6-1, were obtained from the ATCC and cultured in 
RPMI 1640 medium supplemented with penicillin (100 U/ml), strepto- 
mycin (100/tg/ml), and 10% heat-inactivated f tal calf serum. 
2.3. Induction of apoptosis 
Jurkat cells, 1 x 106/ml, were incubated with anti-Fas (50 ng/ml) for 
various periods at 370C, collected and stained with Trypan blue to 
estimate the ratio of non-viable cells. 
2.4. DNA gel electrophoresis 
The DNA fraction of Jurkat cells was prepared by the method e- 
scribed by Takahashi et al. [10] and resolved on 1% agarose gel contain- 
ing 0.05/zg/ml ethidium bromide. DNA bands were visualized by UV 
light. 
2.5. Flow cytometry 
Cells exposed to anti-Fas (l x 106) were washed twice with phos- 
phate-buffered saline (PBS), containing 0.1% bovine serum albumin 
(BSA) and 0.1% NAN3, then suspended in 80% human serum. After 
incubation for 30 min at 37°C, the cells were washed twice with PBS- 
BSA buffer, suspended in the same buffer, then incubated with anti-C3b 
mAb (10/1g/m!) for 30 min at 4°C. After two washes with the PBS-BSA 
buffer, the cells were incubated with FITC-conjugated goat anti-mouse 
IgG (25/zg/ml) for 30 min at 4°C. Cell-bound C3b was then analyzed 
in a Coulter Epics-C cytofluorometer (Coulter Electronics, FL) 
2.6. Analysis of cell-bound C3b 
Jurkat cells (1 x 10 ~) were incubated with anti-Fas (50 ng/ml) for 15 h 
at 370C and mixed with 2 ml of Mg2*-EGTA-90% human serum for 
30 min at 37°C. The cells were washed twice with EDTA-PBS and 
solubilized with l ml of 1% NP-40, containing l0 mM Tris buffer, pH 
7.4, 140 mM NaCl, 0.1% NAN3, 10 mM EDTA, 1 mg/ml of iodoacet- 
amide, and 1 mM phenylmethylsulfonylfluoride (Wako) by vigorous 
agitation for 1 h at 4°C. After centrifugation at 100,000 x g for 1 h, the 
supernatants were collected, mixed with goat anti-C3 antibody 
(2/lg/ml), and immunosorbed bymixing with protein G-plus/protein 
A-agarose (Oncogene Science, Co.) overnight at 4°C. The immuno- 
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sorbed proteins were washed firstly with 20 mM Tris buffer, pH 7.4, 
containing 2 M NaC1 and secondary with 20 mM Tris buffer, pH 7.4, 
containing 0.5% NP-40 and 0.5 M NaCI, and finally with 10 mM Tris, 
pH 7.4. The immunosorbents were mixed with 10 mM Tris buffer, pH 
6.8, containing 1% SDS and 2% 2-mercaptoethanol, then solubilized by 
boiling for 5 min. The sample was divided into two aliquots. One was 
directly resolved by SDS-PAGE according to the method reported by 
Laemmli [11]. Another was mixed with an equal volume of 2 M hydrox- 
ylamine-0.2 M sodium carbonate, pH 10 for 2 h at room temperature, 
dialyzed against 10 mM Tris buffer, pH 6.8, containing 0.5% SDS at 
room temperature, then resolved by SDS-PAGE. Gels were transferred 
to PVDF membranes (Millipore Co.), blocked with 5% non-fat milk 
and reacted with rabbit anti-C3d polyclonal antibody. After washing, 
the blot was incubated with horseradish peroxidase-conjugated goat
anti-rabbit IgG and developed with ECL (Amersham). 
3. Results 
Fig. 1A demonstrates the time dependent death of Jurkat 
cells after treatment with anti-Fas (CH-11). Cell death was 
detectable 3 h after exposure to anti-Fas and reached a plateau 
after 12 h. The rate of cell death was accelerated when Jurkat 
cells were treated with higher concentrations of anti-Fas (data 
not shown). In DNA gel electrophoresis (Fig. 1B), a DNA lad- 
der pattern was detected 2-3 h after exposure to anti-Fas, 
suggesting cell death by apoptosis. Similar results were ob- 
tained when Jurkat cells were treated with another anti-Fas 
mAb, 2D1. Next, we examined whether the apoptotic Jurkat 
cells can activate homologous complement. C3 contains an 
intrac hain thioester bond on the ct chain (110 kDa) and upon 
activation to C3b, forms an ester or amide bond with hydroxyl 
or amino groups on the cell membrane expressing complement 
activators. Thus, complement activation on target cells is ac- 
companied by the deposition of C3b on their surface. Jurkat 
cells exposed to anti-Fas were periodically withdrawn and 
mixed with human serum. Flow cytometry of human serum- 
treated Jurkat cells demonstrated that C3b deposition became 
evident 6h after anti-Fas, treatment and reached aplateau after 
12 h (Fig. 2). This result was in accord with the time course of 
anti-Fas-induced cell death. Evidence that anti-Fas-treated live 
Jurkat cells cannot activate homologous complement indicates 
that the complement activation by Jurkat cells is not induced 
simply by binding with anti-Fas antibody but requires cellular 
events accompanying with apoptotic ell death. The C3b depo- 
sition increased linearly with serum concentrations and reached 
a plateau at about 50% human serum (data not shown), exclud- 
ing the possibility that the C3b deposition is due to the non- 
specific deposition of plasma proteins. 
Complement is activated by two independent cascade sys- 
tems, termed the classical and alternative pathways. The classi- 
cal complement pathway is generally activated by immune com- 
plexes and requires both Ca 2+ and Mg 2+ ions, whereas the 
alternative complement pathway can be activated antibody- 
independently b various molecules on heterologous cells and 
requires only Mg 2+ ions. Apoptotic Jurkat cells were incubated 
with human serum mixed with EDTA (EDTA-serum) or Mg 2+- 
EGTA (Mg2+-EGTA-serum). Fig. 3 shows that C3b was depos- 
ited only when apoptotic Jurkat cells were incubated with 
Mg2+-EGTA human serum, suggesting that the activation of 
alternative, but not the classical pathway is responsible for the 
C3b deposition on apoptotic Jurkat cells. 
To verify that the C3b deposited on apoptotic Jurkat cells is 
covalently bound, C3b deposits were immunoprecipitated with 
anti-C3b, reduced, and Western blotted with anti-C3d anti- 
body. Since the ~ chain of C3b is 105 kDa, immunostained 
bands larger than 105 kDa represent covalent complexes of the 
c( chain of C3b and acceptor molecules on apoptotic cells (Fig. 4). 
Alpha' chain-acceptor complexes larger than 200 kDa were 
cleaved by hydroxylamine, indicating the binding of C3b via an 
ester bond. Two ~'chain-acceptor c mplexes of 130 and 140 
kDa did not dissociate after treatment with hydroxylamine, 
indicating covalent binding via an amido bond. Western blots 
of the hydroxylamine-treated sample revealed a major band of 
65 kDa with a faint band of 105 kDa. C3b is cleaved by the 
complement regulatory enzyme, factor I, at its c~ chain (105 
kDa) to form iC3b, which is composed of three disulfide chains, 
czl (65 kDa), ¢z2 (40 kDa), andfl (70 kDa) [12]. The C3d domain 
is located in the czl chain. Thus, the release of the 65 kDa 
fragment as the major band by hydroxylamine indicated that 
most of C3b deposited on apoptotic cells is converted into iC3b. 
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Fig. 1. (A) Time-dependent death of Jurkat cells upon exposure to anti-Fas mAb. Jurkat cells (1 x 106/ml) were incubated in complete medium 
containing anti-Fas (CH-11, 50 ng/ml) for various periods at 37°C. Cell death (%) : the number of dying cells was estimated by staining with Trypan 
blue. (B) DNA agarose gel electrophoresis of Jurkat cells. Total DNA of Jurkat cells incubated with anti-Fas for indicated period was processed 
and analyzed as described section 2. Molecular sizes in bp are indicated at the left of the gel. 
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Fig. 2. Flow cytometry of C3b deposition on apoptotic Jurkat cells. 
Jurkat cells (1 × 106/ml) were incubated incomplete medium containing 
anti-Fas (CH-11, 50 ng/ml) at 37°C. After incubation for various peri- 
ods, the cells were incubated with 80% normal human serum for 30 min 
at 37°C. C3b deposition was measured by EPICS analysis as described 
in section 2. The vertical and horizontal axes express the cell number 
and the fluorescence intensity, respectively. 
pressed on the surface of homologous cells. We found that 
apoptotic HUVEC can activate the alternative pathway of 
human complement, suggesting that apoptosis i accompanied 
by the expression of the complement activator molecule on 
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Fig. 3. Effect of EDTA and EGTA upon C3b deposition on apoptotic 
Jurkat cells. Jurkat cells were incubated with anti-Fas (CH-11, 50 ng/ 
ml) for 15 h at 37°C, then were incubated with 80% human serum 
containing 20% saline (normal serum), 80% human serum containing 
20% saline and 10 mM EDTA (EDTA + serum), or 80% human serum 
containing 20% saline, 30 mM EGTA, and 35 mM MgCI: (EGTA + 
serum). Normal Jurkat cells were similarly incubated. C3b deposition 
was assessed by flow cytometry as described in section 2. 
apoptotic ell surface [9]. Apoptosis of T cells has attracted 
considerable interest because it plays a pivotal role in the neg- 
ative selection of self-reactive T cells. In this study we examined 
whether apoptotic T cells, such as HUVEC, can activate the 
homologous altemative complement pathway. 
Jurkat cells, a malignant human T cell line, induce apoptosis 
upon exposure to a monoclonal ntibody against human Fas 
antigen [10]. We treated Jurkat cells with anti-Fas mAb, then 
assessed the cell death and C3b deposition, which represents he 
degree of homologous complement activation. Although mAb- 
treated Jurkat cells can be regarded as a type of immune com- 
plex, they failed to activate human complement unless they died 
of apoptosis. These results uggest that the homologous com- 
plement activation is not induced simply by the binding of 
anti-Fas mAb to Jurkat cells. In addition, the C3b deposition 
on apoptotic Jurkat cells seems to occur via the alternative 
complement pathway, as is true of apoptotic HUVEC [9]. 
The activation of the alternative complement pathway re- 
quires activators, which allow the amplification loop of comple- 
ment activation on target cells. Malignant human leukemia B
cell lines, such as Daudi and Raji cells, can activate the alterna- 
tive pathway of human complement. CR2 of these B cell lines 
are responsible for the homologous complement activation via 
the alternative pathway [13,14]. Evidence that the degree of C3b 
deposition on anti-Fas-treated Jurkat cells correlates with the 
increase in their death, suggests that an activator molecule is 
expressed on apoptotic Jurkat cells. Whether putative activator 
molecules are de novo synthesized upon apoptosis or simply 
migrate from the cytosol to the cell surface, remains to be 
elucidated. 
Most of the C3b deposited on apoptotic Jurkat cells is con- 
verted into iC3b, which is a ligand for the CR3 of phagocytes. 
This information suggests that with deposits of iC3b, apoptotic 
1 2 3 4 
Fig. 4. Western blot of the C3b deposition on apoptotic Jurkat cells. 
Apoptotic cells prepared as described in the legend to Fig. 3 were 
incubated with 90% EGTA-serum. C3b deposition was collected by 
immunoprecipitation, resolved by SDS-PAGE, and Western blotted as 
described in section 2. Lane 1, reduced C3b (0.2 pg); lane 2, im- 
munoprecipitates of EGTA-serum-treated apoptotic ells; lane 3, hy- 
droxylamine-treated lane 2 sample; lane 4, reduced iC3b (0.3 pg). 
422 H. Matsui et al./FEBS Letters 351 (1994) 419~122 
cells are processed promptly by phagocytes. We found the that 
phagocytosis of immune complexes by neutrophils becomes 
enhanced when Clq is deposited upon immune complexes and 
that active oxygen formed during the processing of Clq-im- 
mune complexes in phagosomes i  not released extracellularly 
(Ohkuro et al., submitted). It is of interest o assess whether 
iC3b-deposition accelerates the processing of apoptotic ells by 
phagocytes without releasing harmful cellular components 
causing secondary tissue damage. 
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